Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. 

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Hematology 23-Nov-20 18-Jan-21 5-Feb-21
Immunology – (ozanimod) Multiple Sclerosis 26-Mar-21 3-May-21 21-May-21
Immunology – (ozanimod) Ulcerative colitis 2-Dec-20 4-Jan-21 29-Jan-21
Immunology - (abatacept) 9-Dec-20 18-Jan-21 5-Feb-21
Oncology 1-Mar-21 29-Mar-21 23-Apr-21
Immunology – TYK2 (deucravacitinib) 8-Mar-21 12-Apr-21 14-May-21

 


Multiple Sclerosis – Zeposia (ozanimod) ISR Areas of Interest – 2021 RFP Cycle 2 

 

In scope:

  • Ozanimod efficacy and safety in early RMS disease and/or diverse patient populations 
  • RMS disease outcomes to include novel endpoints such as cognition, neuroimaging, biomarkers and/or patient reported outcomes 
  • Exploring the impact of ozanimod on immune function (in vitro/in vivo)
  • Direct effect of ozanimod in the central nervous system using advanced imaging or human cell-based models

Out of scope:

  • Pediatric studies
  • Indications outside of multiple sclerosis
  • Combination with other disease modifying therapies 
  • Alternative dosing other than 0.92 mg QD

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving idecabtagene vicleucel or lisocabtagene maraleucel, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here
     
    Nivolumab + Bempegaldesleukin – Clinical and Non Clinical Research proposals will be accepted from January 15, 2021 to March 15, 2021
     
    Nivolumab + Bempegaldesleukin - Areas of Interest include:
    • Translational studies (Contribution of component, Mechanism of Action, biomarkers of response)
    • Melanoma, RCC, Urothelial clinical studies (ie: expanded patient populations)(includes all settings of disease)
    • Real World Data or Data investigating endpoints or surrogates of response/survival

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application